Autoantibodies specific for the phospholipase A 2 receptor in recurrent and de novo membranous nephropathy

American Journal of Transplantation

Volumn 11, Issue 10, 2011, Pages 2144-2152

  Debiec, H ^a,b,c   Martin, L ^d,e   Jouanneau, C ^a,b   Dautin, G ^f   Mesnard, L ^a,b,c   Rondeau, E ^a,b,c   Mousson, C ^d,e   Ronco, P ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL TENON   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE BOURGOGNE   (France)

^f Blood French Agency de Bourgogne Franche Comté   (France)

Author keywords

De novo; membranous nephropathy; PLA 2R1; recurrent

Indexed keywords

AUTOANTIBODY; COMPLEMENTARY DNA; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELL STRAIN HEK293; CLINICAL ARTICLE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT;

ADULT; AUTOANTIBODIES; DNA, COMPLEMENTARY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, PHOSPHOLIPASE A2; RECURRENCE;

EID: 80053301363     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03643.x     Document Type: Article

References (22)

1. Glassock RJ,. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003; 23: 324-332. (Pubitemid 37022035)
2. Schwarz A, Krause PH, Offermann G, Keller F,. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. Transplantation 1994; 58: 650-654. (Pubitemid 24317761)
3. Ponticelli C, Glassock RJ,. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010; 5: 2363-2372.
4. Monga G, Mazzucco G, Basolo B, et al,. Membranous glomerulonephritis (MGN) in transplanted kidneys: Morphologic investigation on 256 renal allografts. Mod Pathol 1993; 6: 249-258.
5. Cosyns JP, Couchoud C, Pouteil-Noble C, Squifflet JP, Pirson Y,. Recurrence of membranous nephropathy after renal transplantation: Probability, outcome and risk factors. Clin Nephrol 1998; 50: 144-153. (Pubitemid 28434742)
6. Poduval RD, Josephson MA, Javaid B,. Treatment of de novo and recurrent membranous nephropathy in renal transplant patients. Semin Nephrol 2003; 23: 392-399. (Pubitemid 37022043)
7. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ,. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103-109. (Pubitemid 34753480)
8. Dabade TS, Grande JP, Norby SM, Fervenza FC, Cosio FG,. Recurrent idiopathic membranous nephropathy after kidney transplantation: A surveillance biopsy study. Am J Transplant 2008; 8: 1318-1322. (Pubitemid 351763689)
9. Aline-Fardin A, Rifle G, Martin L, et al,. Recurent and de novo membranous glomerulopathy after kidney transplantation. Transplant Proc 2009; 41: 669-671.
10. Debiec H, Guigonis V, Mougenot B, et al,. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346: 2053-2060. (Pubitemid 34680597)
11. Honda K, Horita S, Toki D, et al,. De novo membranous nephropathy and antibody-mediated rejection in transplanted kidney. Clin Transplant. 2010; 25: 191-200.
12. Beck LH, Jr,., Bonegio RG, Lambeau G, et al,. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
13. Stahl R, Hoxha E, Fechner K,. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010; 363: 496-498.
14. El-Zoghby ZM, Grande JP, Fraile MG, et al,. Recurrent idiopathic membranous nephropathy: Early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009; 9: 2800-2807.
15. Sprangers B, Lefkowitz GI, Cohen SD, et al,. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010; 5: 790-797.
16. Debiec H, Ronco P,. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. New Engl J Med 2011; 364: 689-690.
17. Knehtl M, Debiec H, Kamgang P, et al,. A case of phospholipase A(2) receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am J Kidney Dis 2011; 57: 140-143.
18. El Kossi M, Harmer A, Goodwin J, et al,. De novo membranous nephropathy associated with donor-specific alloantibody. Clin Transplant 2008; 22: 124-127. (Pubitemid 351150013)
19. Stanescu HC, Arcos-Burgos M, Medlar A, et al,. Risk HLA-DQA1 and PLA2R1 alleles and idiopathic membranous nephropathy. New Engl J Med 2011; 364: 616-626.
20. Prunotto M, Carnevali ML, Candiano G, et al,. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21: 507-519.
21. Liu YH, Chen CH, Chen SY, et al,. Association of phospholipase A2 receptor 1 polymorphisms with diopathic membranous nephropathy in Chinese patients in Taiwan. J Biomed Sci 2010; 17: 81-88.
22. Rifle G, Mousson C, Martin L, Guignier F, Hajji K,. Donor-specific antibodies in allograft rejection: Clinical and experimental data. Transplantation 2005; 79 (suppl): S14-S18. (Pubitemid 40293566)